{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:58:49Z","timestamp":1781139529864,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13422-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:34:55Z","timestamp":1777034095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Workflow-embedded automation improves hepatitis B screening and safety in b\/tsDMARD users"],"prefix":"10.1186","volume":"26","author":[{"given":"Meng Hsuan","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsueh","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Tzu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning-Sheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"1","key":"13422_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","volume":"81","author":"G Nagy","year":"2022","unstructured":"Nagy G, Roodenrijs NMT, Welsing PMJ, Kedves M, Hamar A, van der Goes MC, Kent A, Bakkers M, Pchelnikova P, Blaas E, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022;81(1):20\u201333.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"13422_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/1744666X.2024.2327589","volume":"20","author":"R Abedalweli","year":"2024","unstructured":"Abedalweli R, Nguyen M, Deodhar A. Combination biologics or targeted synthetic disease-modifying anti-rheumatic drugs in the treatment of spondyloarthritis: a systematic literature review. Expert Rev Clin Immunol. 2024;20(7):735\u201343.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"13422_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/BOR.0000000000000995","volume":"36","author":"K Barth","year":"2024","unstructured":"Barth K, Gill H, Singh N. Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology. Curr Opin Rheumatol. 2024;36(2):113\u20139.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"13422_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1136\/ard-2022-223357","volume":"82","author":"A Sepriano","year":"2023","unstructured":"Sepriano A, Kerschbaumer A, Bergstra SA, Smolen JS, van der Heijde D, Caporali R, Edwards CJ, Verschueren P, de Souza S, Pope J, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2023;82(1):107\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"13422_CR5","doi-asserted-by":"publisher","first-page":"e70372","DOI":"10.1111\/1756-185x.70372","volume":"28","author":"YY Leung","year":"2025","unstructured":"Leung YY, Bird P, Haroon M, Kishimoto M, Shin K, Mathew AJ, Reyes H, Chau J, Neuen D, Chiowchanwisawakit P, et al. The APLAR Recommendations for the Management of Psoriatic Arthritis. Int J Rheum Dis. 2025;28(8):e70372.","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"13422_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/liv.15793","volume":"44","author":"MH Kuo","year":"2024","unstructured":"Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. HBV reactivation in HBsAg-\/HBcAb+ rheumatoid arthritis patients receiving biologic\/targeted synthetic DMARDs. Liver Int. 2024;44(2):497\u2013507.","journal-title":"Liver Int"},{"issue":"6","key":"13422_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY, Kao JH, Terrault N, Lok AS, Reddy KR. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. J Hepatol. 2022;77(6):1670\u201389.","journal-title":"J Hepatol"},{"issue":"1","key":"13422_CR8","first-page":"e0143","volume":"23","author":"C Mezzacappa","year":"2024","unstructured":"Mezzacappa C, Lim JK. Management of HBV reactivation: Challenges and opportunities. Clin Liver Dis (Hoboken). 2024;23(1):e0143.","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"10","key":"13422_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3748\/wjg.v30.i10.1295","volume":"30","author":"H Ma","year":"2024","unstructured":"Ma H, Yan QZ, Ma JR, Li DF, Yang JL. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World J Gastroenterol. 2024;30(10):1295\u2013312.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"13422_CR10","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1111\/liv.70152","volume":"45","author":"MH Kuo","year":"2025","unstructured":"Kuo MH, Tseng CW, Tseng KC, Lu MC, Tung CH, Chen NT, Huang KY, Lai NS. The Relationship Between TNF-alpha Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders. Liver Int. 2025;45(6):e70152.","journal-title":"Liver Int"},{"key":"13422_CR11","doi-asserted-by":"crossref","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, B\u00f6hm P, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. 2023;82(6):742\u201353.","DOI":"10.1136\/ard-2022-223335"},{"key":"13422_CR12","unstructured":"Sammaritano LR, Askanase A, Bermas BL, Dall\u2019Era M, Duarte-Garc\u00eda A, Hiraki LT, Son MBF, Werth VP, Aranow C, Barnado A, et al. 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. n\/a(n\/a)."},{"issue":"6","key":"13422_CR13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.semarthrit.2020.03.003","volume":"50","author":"G Schmajuk","year":"2020","unstructured":"Schmajuk G, Li J, Evans M, Anastasiou C, Izadi Z, Kay JL, Hammam N, Yazdany J. RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Semin Arthritis Rheum. 2020;50(6):1542\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"13422_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/acr.23241","volume":"70","author":"TC Lin","year":"2018","unstructured":"Lin TC, Hashemi N, Kim SC, Yang YK, Yoshida K, Tedeschi S, Desai R, Solomon DH. Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. Arthritis Care Res (Hoboken). 2018;70(1):30\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"13422_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40780-024-00339-9","volume":"10","author":"Y Yanagisawa","year":"2024","unstructured":"Yanagisawa Y, Imai S, Kizaki H, Hori S. A cross-sectional survey of hepatitis B virus screening in patients who received immunosuppressive therapy for rheumatoid arthritis in Japan. J Pharm Health Care Sci. 2024;10(1):18.","journal-title":"J Pharm Health Care Sci"},{"issue":"1","key":"13422_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3899\/jrheum.211000","volume":"49","author":"A Aguirre","year":"2022","unstructured":"Aguirre A, Yazdany J. Hepatitis B Screening Before Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drug Therapy: Many Roads to Improvement. J Rheumatol. 2022;49(1):1\u20134.","journal-title":"J Rheumatol"},{"issue":"1","key":"13422_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3899\/jrheum.210257","volume":"49","author":"AM Mohareb","year":"2022","unstructured":"Mohareb AM, Patel NJ, Fu X, Kim AY, Wallace ZS, Hyle EP. Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study. J Rheumatol. 2022;49(1):104\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"13422_CR18","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"13422_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jvh.13985","volume":"31","author":"GA Yendewa","year":"2024","unstructured":"Yendewa GA, Salata RA, Olasehinde T, Mulindwa F, Jacobson JM, Mohareb AM. Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013\u20132017: A nationwide population-based study. J Viral Hepat. 2024;31(11):657\u201369.","journal-title":"J Viral Hepat"},{"issue":"11","key":"13422_CR20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/1055-9965.EPI-18-0448","volume":"27","author":"E Chak","year":"2018","unstructured":"Chak E, Taefi A, Li CS, Chen MS Jr., Harris AM, MacDonald S, Bowlus C. Electronic Medical Alerts Increase Screening for Chronic Hepatitis B: A Randomized, Double-Blind, Controlled Trial. Cancer Epidemiol Biomarkers Prev. 2018;27(11):1352\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"13422_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5152\/tjg.2023.22297","volume":"34","author":"A K\u00f6ksal","year":"2023","unstructured":"K\u00f6ksal A, Toka B, Sade\u00e7olak M, Acar \u015e, Eminler AT, Tozlu M, Karabay O. Electronic Alert System Significantly Increases HBV Screening Rates Before Immunosuppressive Treatments. Turk J Gastroenterol. 2023;34(5):552\u20139.","journal-title":"Turk J Gastroenterol"},{"issue":"7494","key":"13422_CR22","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/bmj.38398.500764.8F","volume":"330","author":"K Kawamoto","year":"2005","unstructured":"Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ. 2005;330(7494):765.","journal-title":"BMJ"},{"issue":"4","key":"13422_CR23","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr., Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560\u201399.","journal-title":"Hepatology"},{"key":"13422_CR24","doi-asserted-by":"crossref","unstructured":"Liu CJ, Chen PJ. Elimination of Hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead. Viruses. 2020;12(8).","DOI":"10.3390\/v12080815"},{"issue":"6","key":"13422_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3747\/co.v17i6.653","volume":"17","author":"R Lee","year":"2010","unstructured":"Lee R, Vu K, Bell CM, Hicks LK. Screening for hepatitis B surface antigen before chemotherapy: current practice and opportunities for improvement. Curr Oncol. 2010;17(6):32\u20138.","journal-title":"Curr Oncol"},{"issue":"1","key":"13422_CR26","first-page":"19","volume":"77","author":"K Leber","year":"2019","unstructured":"Leber K, Otten J, Depla A, Brandjes DPM, Lauw FN. Introduction of routine hepatitis B screening for all patients receiving cancer treatment. Neth J Med. 2019;77(1):19\u201324.","journal-title":"Neth J Med"},{"key":"13422_CR27","doi-asserted-by":"crossref","unstructured":"Mah SJ, Bellini J, Zhao L, Nguyen JMV, Reade CJ, Jimenez W, Carlson V, Kumar Tyagi NJ, Bernard L, Pond GR. Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: a quality improvement initiative. In: American Society of Clinical Oncology. 2022.","DOI":"10.1200\/JCO.2022.40.28_suppl.332"},{"key":"13422_CR28","doi-asserted-by":"publisher","first-page":"e58036","DOI":"10.2196\/58036","volume":"13","author":"K Grechuta","year":"2024","unstructured":"Grechuta K, Shokouh P, Alhussein A, M\u00fcller-Wieland D, Meyerhoff J, Gilbert J, Purushotham S, Rolland C. Benefits of Clinical Decision Support Systems for the Management of Noncommunicable Chronic Diseases: Targeted Literature Review. Interact J Med Res. 2024;13:e58036.","journal-title":"Interact J Med Res"},{"issue":"1","key":"13422_CR29","doi-asserted-by":"publisher","first-page":"e14363","DOI":"10.1111\/1475-6773.14363","volume":"60","author":"G Schmajuk","year":"2025","unstructured":"Schmajuk G, Ware A, Li J, Tarasovsky G, Shiboski S, Barton JL, Miller KL, Mitchell HA, Dana J, Reiter K, et al. National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease-modifying agent users within the Veterans Health Administration. Health Serv Res. 2025;60(1):e14363.","journal-title":"Health Serv Res"},{"issue":"2","key":"13422_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/acr.25181","volume":"77","author":"H Baker","year":"2025","unstructured":"Baker H, Fine R, Suter F, Allore H, Hsiao B, Chowdhary V, Lavelle E, Chen P, Hintz R, Suter LG, et al. Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs. Arthritis Care Res (Hoboken). 2025;77(2):273\u201381.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"13422_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.27103","volume":"60","author":"B Sampedro","year":"2014","unstructured":"Sampedro B, Hern\u00e1ndez-L\u00f3pez C, Ferrandiz JR, Illaro A, F\u00e1brega E, Cuadrado A, Iruzubieta P, Men\u00e9ndez S, Cabezas J, Crespo J. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. Hepatology. 2014;60(1):106\u201313.","journal-title":"Hepatology"},{"issue":"2","key":"13422_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali FS, Nguyen MH, Hernaez R, Huang DQ, Wilder J, Piscoya A, Simon TG, Falck-Ytter Y. AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals. Gastroenterology. 2025;168(2):267\u201384.","journal-title":"Gastroenterology"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13422-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13422-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:06:55Z","timestamp":1781136415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13422-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13422"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13422-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the ethical standards of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of the Dalin Tzu Chi General Hospital (B11501003). The requirement for informed consent was waived owing to the retrospective design and the use of anonymized patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1111"}}